VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
VYNE Therapeutics Inc. announced its participation in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference. David Domzalski, President, and CEO, along with Dr. Iain Stuart, CSO, will engage in a fireside chat on March 28, 2024, discussing innovative therapies for immuno-inflammatory conditions.
03/19/2024 - 08:00 AM
BRIDGEWATER, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer, and Dr. Iain Stuart, Chief Scientific Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference (Skin Diseases, Conditions and Disorders) being held on Thursday, March 28, 2024.
HCW Conference Details:
Fireside Chat: Thursday, March 28, 2024, at 8:30 am ET Speakers: David Domzalski, President and Chief Executive Officer Registration: Webcast Link
The replay of the webcast will be available on the VYNE website for 90 days following the conference.
About VYNE Therapeutics Inc.
For more information about VYNE Therapeutics Inc. or its product candidates, visit www.vynetherapeutics.com. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.
Investor Relations: jfraunces@lifesciadvisors.com
Tyler ZerondaTyler.Zeronda@VYNEtx.com
When is the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference taking place?
The conference is scheduled for Thursday, March 28, 2024.
Who will be participating in the fireside chat at the conference from VYNE Therapeutics Inc.?
David Domzalski, President, and Chief Executive Officer, along with Dr. Iain Stuart, Chief Scientific Officer.
What is the focus of VYNE Therapeutics Inc. in terms of developing therapies?
VYNE is focused on developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions.
Where can the replay of the webcast be accessed?
The replay will be available on the VYNE website for 90 days following the conference.
VYNE Rankings
N/A Ranked by Stock Gains
VYNE Stock Data
Industry
Medicinal and Botanical Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major, Manufacturing, Medicinal and Botanical Manufacturing
About VYNE
vyne therapeutics inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. it offers amzeeq, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. the company is also developing fmx103, which is in phase iii clinical trials for the treatment of moderate-to-severe papulopustular rosacea in adults; and fcd105, a topical combination foam that is in phase ii clinical trials for the treatment of moderate-to-severe acne vulgaris. in addition, it is developing serlopitant, a once-daily oral nk1 receptor antagonist, used as a treatment option for pruritus associated with prurigo nodularis. the company was formerly known as menlo therapeutics inc. and changed its name to vyne therapeutics inc. in september 2020. vyne therapeutics inc. was founded in 2003 and is headquartered in bridgewater, new jersey.
